Hepatitis B seroprevalence in hematological oncology patients
Objectives: Hepatitis B virus (HBV) infection is still a serious public health problem today. Many factors such as frequent blood transfusion, hemodialysis, sexual contact, sterilization in surgical procedures, etc. are involved in the transmission of hepatitis B virus. In our study, HBV seroprevale...
Gespeichert in:
| Veröffentlicht in: | The European research journal 2020-01, Vol.6 (2), p.87-91 |
|---|---|
| Hauptverfasser: | , , , , , |
| Format: | Artikel |
| Sprache: | eng |
| Schlagworte: | |
| Online-Zugang: | Volltext |
| Tags: |
Tag hinzufügen
Keine Tags, Fügen Sie den ersten Tag hinzu!
|
| container_end_page | 91 |
|---|---|
| container_issue | 2 |
| container_start_page | 87 |
| container_title | The European research journal |
| container_volume | 6 |
| creator | Türken, Melda Köse, Şükran Acar, Ayşe Özkan Ceylan, Cengiz Albayrak, Hazal Arkalı, Eren |
| description | Objectives: Hepatitis B virus (HBV) infection is still a serious public health problem today. Many factors such as frequent blood transfusion, hemodialysis, sexual contact, sterilization in surgical procedures, etc. are involved in the transmission of hepatitis B virus. In our study, HBV seroprevalence was evaluated retrospectively in order to provide vaccination of anti-HBs negative patients and to determine HBV prophylaxis in patients with hematological malignancy. Methods: A total of499 patients were included in the study. HBsAg, anti-HBs, anti-HBc IgG, anti-HDV, HBV DNA values were measured by ELISA (enzyme-linked immunosorbent assay, Liason, Diasorin, Italy) with Real-Time PCR (Cobas-Tagman, Roche Switzerland) and recorded. The obtained datas were evaluated by SPSS for Windows 15.00 statistical program. A value ofp |
| doi_str_mv | 10.18621/eurj473241 |
| format | Article |
| fullrecord | <record><control><sourceid>proquest</sourceid><recordid>TN_cdi_proquest_journals_2418819132</recordid><sourceformat>XML</sourceformat><sourcesystem>PC</sourcesystem><sourcerecordid>2418819132</sourcerecordid><originalsourceid>FETCH-proquest_journals_24188191323</originalsourceid><addsrcrecordid>eNqNjkEKwjAURIMgWLQrLxBwXc1PQk0XbhSlB3BfQvlqSkxqkgre3hY8gKsZePNgCFkD24IqOexwCJ3cCy5hRjIOsioEqGpB8hg7xhgoKKVgGTnU2Otkkon0SCMG3wd8a4uuRWocfeBTJ2_93bTaUu_aqX_opKBLcUXmN20j5r9cks3lfD3VRR_8a8CYms4PwY2oGZ8oBRUILv5bfQFiIz1g</addsrcrecordid><sourcetype>Aggregation Database</sourcetype><iscdi>true</iscdi><recordtype>article</recordtype><pqid>2418819132</pqid></control><display><type>article</type><title>Hepatitis B seroprevalence in hematological oncology patients</title><source>EZB-FREE-00999 freely available EZB journals</source><creator>Türken, Melda ; Köse, Şükran ; Acar, Ayşe Özkan ; Ceylan, Cengiz ; Albayrak, Hazal ; Arkalı, Eren</creator><creatorcontrib>Türken, Melda ; Köse, Şükran ; Acar, Ayşe Özkan ; Ceylan, Cengiz ; Albayrak, Hazal ; Arkalı, Eren</creatorcontrib><description>Objectives: Hepatitis B virus (HBV) infection is still a serious public health problem today. Many factors such as frequent blood transfusion, hemodialysis, sexual contact, sterilization in surgical procedures, etc. are involved in the transmission of hepatitis B virus. In our study, HBV seroprevalence was evaluated retrospectively in order to provide vaccination of anti-HBs negative patients and to determine HBV prophylaxis in patients with hematological malignancy. Methods: A total of499 patients were included in the study. HBsAg, anti-HBs, anti-HBc IgG, anti-HDV, HBV DNA values were measured by ELISA (enzyme-linked immunosorbent assay, Liason, Diasorin, Italy) with Real-Time PCR (Cobas-Tagman, Roche Switzerland) and recorded. The obtained datas were evaluated by SPSS for Windows 15.00 statistical program. A value ofp <0.05 was accepted as a statistical significance value. Results: HBsAg positivity was found to be 3.4% (n = 17) in all patients. Appropriate treatment regimens were started to patients with HBsAg (+). There were 166 (33.3%) patients with anti-HBs (+). One hundred nineteen (23.8%) patients had anti-HBc IgG (+), 40 (33.6%) of them were started a prophylactic treatment regimen. Anti-HBs positivity were reported after vaccination in 48 (16.8%) patients. Occult hepatitis have not been detected in patients with anti-HBc IgG positivity. Conclusions: As a result of this study, anti-HBs negative patients with hematological malignancies were vaccinated. Patients and physicians should be informed about vaccination and hepatitis serology controls of hematological malignancy and other immunosuppressed patients. Sensitivity in this context should be increased in terms of prophylactic treatments.</description><identifier>EISSN: 2149-3189</identifier><identifier>DOI: 10.18621/eurj473241</identifier><language>eng</language><publisher>Bursa: The Association of Health Research & Strategy</publisher><subject>Health risk assessment ; Hematology ; Hepatitis B ; Immunization</subject><ispartof>The European research journal, 2020-01, Vol.6 (2), p.87-91</ispartof><rights>Copyright The Association of Health Research & Strategy 2020</rights><lds50>peer_reviewed</lds50><woscitedreferencessubscribed>false</woscitedreferencessubscribed></display><links><openurl>$$Topenurl_article</openurl><openurlfulltext>$$Topenurlfull_article</openurlfulltext><thumbnail>$$Tsyndetics_thumb_exl</thumbnail><link.rule.ids>314,780,784,27924,27925</link.rule.ids></links><search><creatorcontrib>Türken, Melda</creatorcontrib><creatorcontrib>Köse, Şükran</creatorcontrib><creatorcontrib>Acar, Ayşe Özkan</creatorcontrib><creatorcontrib>Ceylan, Cengiz</creatorcontrib><creatorcontrib>Albayrak, Hazal</creatorcontrib><creatorcontrib>Arkalı, Eren</creatorcontrib><title>Hepatitis B seroprevalence in hematological oncology patients</title><title>The European research journal</title><description>Objectives: Hepatitis B virus (HBV) infection is still a serious public health problem today. Many factors such as frequent blood transfusion, hemodialysis, sexual contact, sterilization in surgical procedures, etc. are involved in the transmission of hepatitis B virus. In our study, HBV seroprevalence was evaluated retrospectively in order to provide vaccination of anti-HBs negative patients and to determine HBV prophylaxis in patients with hematological malignancy. Methods: A total of499 patients were included in the study. HBsAg, anti-HBs, anti-HBc IgG, anti-HDV, HBV DNA values were measured by ELISA (enzyme-linked immunosorbent assay, Liason, Diasorin, Italy) with Real-Time PCR (Cobas-Tagman, Roche Switzerland) and recorded. The obtained datas were evaluated by SPSS for Windows 15.00 statistical program. A value ofp <0.05 was accepted as a statistical significance value. Results: HBsAg positivity was found to be 3.4% (n = 17) in all patients. Appropriate treatment regimens were started to patients with HBsAg (+). There were 166 (33.3%) patients with anti-HBs (+). One hundred nineteen (23.8%) patients had anti-HBc IgG (+), 40 (33.6%) of them were started a prophylactic treatment regimen. Anti-HBs positivity were reported after vaccination in 48 (16.8%) patients. Occult hepatitis have not been detected in patients with anti-HBc IgG positivity. Conclusions: As a result of this study, anti-HBs negative patients with hematological malignancies were vaccinated. Patients and physicians should be informed about vaccination and hepatitis serology controls of hematological malignancy and other immunosuppressed patients. Sensitivity in this context should be increased in terms of prophylactic treatments.</description><subject>Health risk assessment</subject><subject>Hematology</subject><subject>Hepatitis B</subject><subject>Immunization</subject><issn>2149-3189</issn><fulltext>true</fulltext><rsrctype>article</rsrctype><creationdate>2020</creationdate><recordtype>article</recordtype><sourceid>ABUWG</sourceid><sourceid>AFKRA</sourceid><sourceid>BENPR</sourceid><sourceid>CCPQU</sourceid><recordid>eNqNjkEKwjAURIMgWLQrLxBwXc1PQk0XbhSlB3BfQvlqSkxqkgre3hY8gKsZePNgCFkD24IqOexwCJ3cCy5hRjIOsioEqGpB8hg7xhgoKKVgGTnU2Otkkon0SCMG3wd8a4uuRWocfeBTJ2_93bTaUu_aqX_opKBLcUXmN20j5r9cks3lfD3VRR_8a8CYms4PwY2oGZ8oBRUILv5bfQFiIz1g</recordid><startdate>20200101</startdate><enddate>20200101</enddate><creator>Türken, Melda</creator><creator>Köse, Şükran</creator><creator>Acar, Ayşe Özkan</creator><creator>Ceylan, Cengiz</creator><creator>Albayrak, Hazal</creator><creator>Arkalı, Eren</creator><general>The Association of Health Research & Strategy</general><scope>ABUWG</scope><scope>AFKRA</scope><scope>BENPR</scope><scope>CCPQU</scope><scope>EDSIH</scope><scope>PQEST</scope><scope>PQQKQ</scope><scope>PQUKI</scope><scope>PRINS</scope></search><sort><creationdate>20200101</creationdate><title>Hepatitis B seroprevalence in hematological oncology patients</title><author>Türken, Melda ; Köse, Şükran ; Acar, Ayşe Özkan ; Ceylan, Cengiz ; Albayrak, Hazal ; Arkalı, Eren</author></sort><facets><frbrtype>5</frbrtype><frbrgroupid>cdi_FETCH-proquest_journals_24188191323</frbrgroupid><rsrctype>articles</rsrctype><prefilter>articles</prefilter><language>eng</language><creationdate>2020</creationdate><topic>Health risk assessment</topic><topic>Hematology</topic><topic>Hepatitis B</topic><topic>Immunization</topic><toplevel>peer_reviewed</toplevel><toplevel>online_resources</toplevel><creatorcontrib>Türken, Melda</creatorcontrib><creatorcontrib>Köse, Şükran</creatorcontrib><creatorcontrib>Acar, Ayşe Özkan</creatorcontrib><creatorcontrib>Ceylan, Cengiz</creatorcontrib><creatorcontrib>Albayrak, Hazal</creatorcontrib><creatorcontrib>Arkalı, Eren</creatorcontrib><collection>ProQuest Central (Alumni Edition)</collection><collection>ProQuest Central UK/Ireland</collection><collection>ProQuest Central</collection><collection>ProQuest One Community College</collection><collection>Turkey Database</collection><collection>ProQuest One Academic Eastern Edition (DO NOT USE)</collection><collection>ProQuest One Academic</collection><collection>ProQuest One Academic UKI Edition</collection><collection>ProQuest Central China</collection><jtitle>The European research journal</jtitle></facets><delivery><delcategory>Remote Search Resource</delcategory><fulltext>fulltext</fulltext></delivery><addata><au>Türken, Melda</au><au>Köse, Şükran</au><au>Acar, Ayşe Özkan</au><au>Ceylan, Cengiz</au><au>Albayrak, Hazal</au><au>Arkalı, Eren</au><format>journal</format><genre>article</genre><ristype>JOUR</ristype><atitle>Hepatitis B seroprevalence in hematological oncology patients</atitle><jtitle>The European research journal</jtitle><date>2020-01-01</date><risdate>2020</risdate><volume>6</volume><issue>2</issue><spage>87</spage><epage>91</epage><pages>87-91</pages><eissn>2149-3189</eissn><abstract>Objectives: Hepatitis B virus (HBV) infection is still a serious public health problem today. Many factors such as frequent blood transfusion, hemodialysis, sexual contact, sterilization in surgical procedures, etc. are involved in the transmission of hepatitis B virus. In our study, HBV seroprevalence was evaluated retrospectively in order to provide vaccination of anti-HBs negative patients and to determine HBV prophylaxis in patients with hematological malignancy. Methods: A total of499 patients were included in the study. HBsAg, anti-HBs, anti-HBc IgG, anti-HDV, HBV DNA values were measured by ELISA (enzyme-linked immunosorbent assay, Liason, Diasorin, Italy) with Real-Time PCR (Cobas-Tagman, Roche Switzerland) and recorded. The obtained datas were evaluated by SPSS for Windows 15.00 statistical program. A value ofp <0.05 was accepted as a statistical significance value. Results: HBsAg positivity was found to be 3.4% (n = 17) in all patients. Appropriate treatment regimens were started to patients with HBsAg (+). There were 166 (33.3%) patients with anti-HBs (+). One hundred nineteen (23.8%) patients had anti-HBc IgG (+), 40 (33.6%) of them were started a prophylactic treatment regimen. Anti-HBs positivity were reported after vaccination in 48 (16.8%) patients. Occult hepatitis have not been detected in patients with anti-HBc IgG positivity. Conclusions: As a result of this study, anti-HBs negative patients with hematological malignancies were vaccinated. Patients and physicians should be informed about vaccination and hepatitis serology controls of hematological malignancy and other immunosuppressed patients. Sensitivity in this context should be increased in terms of prophylactic treatments.</abstract><cop>Bursa</cop><pub>The Association of Health Research & Strategy</pub><doi>10.18621/eurj473241</doi></addata></record> |
| fulltext | fulltext |
| identifier | EISSN: 2149-3189 |
| ispartof | The European research journal, 2020-01, Vol.6 (2), p.87-91 |
| issn | 2149-3189 |
| language | eng |
| recordid | cdi_proquest_journals_2418819132 |
| source | EZB-FREE-00999 freely available EZB journals |
| subjects | Health risk assessment Hematology Hepatitis B Immunization |
| title | Hepatitis B seroprevalence in hematological oncology patients |
| url | https://sfx.bib-bvb.de/sfx_tum?ctx_ver=Z39.88-2004&ctx_enc=info:ofi/enc:UTF-8&ctx_tim=2024-12-29T21%3A20%3A22IST&url_ver=Z39.88-2004&url_ctx_fmt=infofi/fmt:kev:mtx:ctx&rfr_id=info:sid/primo.exlibrisgroup.com:primo3-Article-proquest&rft_val_fmt=info:ofi/fmt:kev:mtx:journal&rft.genre=article&rft.atitle=Hepatitis%20B%20seroprevalence%20in%20hematological%20oncology%20patients&rft.jtitle=The%20European%20research%20journal&rft.au=T%C3%BCrken,%20Melda&rft.date=2020-01-01&rft.volume=6&rft.issue=2&rft.spage=87&rft.epage=91&rft.pages=87-91&rft.eissn=2149-3189&rft_id=info:doi/10.18621/eurj473241&rft_dat=%3Cproquest%3E2418819132%3C/proquest%3E%3Curl%3E%3C/url%3E&disable_directlink=true&sfx.directlink=off&sfx.report_link=0&rft_id=info:oai/&rft_pqid=2418819132&rft_id=info:pmid/&rfr_iscdi=true |